Linezolid-induced serotonin syndrome manifests with a wide spectrum of symptoms, ranging from mild to life-threatening. Early recognition is key for prompt management.
Commonly observed symptoms include altered mental status (e. g., agitation, confusion, delirium), autonomic instability (e. g., tachycardia, hyperthermia, hypertension, diaphoresis), and neuromuscular hyperactivity (e. g., tremor, rigidity, hyperreflexia, myoclonus).
Severity varies significantly. Mild cases present with only a few symptoms, often subtle and easily missed. Severe cases, however, can progress rapidly to include respiratory distress, seizures, and cardiovascular collapse. This necessitates immediate medical intervention.
| Mental Status Changes | Agitation, anxiety, confusion, disorientation, delirium, hallucinations |
| Autonomic Instability | Tachycardia, hypertension, hyperthermia (often >38°C), diaphoresis, flushing |
| Neuromuscular Hyperactivity | Tremor, muscle rigidity, hyperreflexia, clonus, myoclonus, incoordination |
| Gastrointestinal | Nausea, vomiting, diarrhea |
The Hunter Serotonin Toxicity Criteria are a useful tool for assessing the likelihood of serotonin syndrome. This scoring system considers symptoms across the three major categories detailed above. A higher score indicates a greater probability of serotonin syndrome.
Suspect linezolid-induced serotonin syndrome in any patient taking linezolid who presents with a cluster of these symptoms, especially if they are taking other serotonergic drugs concurrently. Immediate discontinuation of linezolid and supportive care are critical steps in management. Specific treatment may include symptomatic management, benzodiazepines, cyproheptadine, and in severe cases, mechanical ventilation and intensive care.
